{"content":"<li class=\"n-box-item date-title\" data-end=\"1387947599\" data-start=\"1387861200\" data-txt=\"Friday, December 20, 2019\">Tuesday, December 24, 2013</li><li class=\"n-box-item sa-box-item\" data-id=\"1481881\" data-ts=\"1387913475\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1481881-after-hour-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hour Gainers / Losers</a></h4><ul>     <li>\n<b>Top gainers:</b> <a href=\"https://seekingalpha.com/symbol/JKS\" title=\"JinkoSolar Holding Co., Ltd.\">JKS</a> <font color=\"green\">+3.7%</font>. <a href=\"https://seekingalpha.com/symbol/YGE\" title=\"Yingli Green Energy Holding Company Limited\">YGE</a> <font color=\"green\">+1.1%</font>. <a href=\"https://seekingalpha.com/symbol/SVXY\" title=\"ProShares Short VIX Short-Term Futures ETF\">SVXY</a> <font color=\"green\">+1.0%</font>. <a href=\"https://seekingalpha.com/symbol/XIV\" title=\"VelocityShares Daily Inverse VIX Short-Term ETN\">XIV</a> <font color=\"green\">+0.9%</font>. <a href=\"https://seekingalpha.com/symbol/PHM\" title=\"PulteGroup, Inc.\">PHM</a> <font color=\"green\">+0.9%</font>.</li>\n<li>\n<b>Top losers:</b> <a href=\"https://seekingalpha.com/symbol/OMER\" title=\"Omeros Corporation\">OMER</a> <font color=\"red\">-7.7%</font>. <a href=\"https://seekingalpha.com/symbol/GDX\" title=\"VanEck Vectors Gold Miners ETF\">GDX</a> <font color=\"red\">-3.0%</font>. <a href=\"https://seekingalpha.com/symbol/UVXY\" title=\"ProShares Ultra VIX Short-Term Futures ETF\">UVXY</a> <font color=\"red\">-1.9%</font>. <a href=\"https://seekingalpha.com/symbol/FXI\" title=\"iShares China Large-Cap ETF\">FXI</a> <font color=\"red\">-1.8%</font>. <a href=\"https://seekingalpha.com/symbol/VIXY\" title=\"ProShares VIX Short-Term Futures ETF\">VIXY</a> <font color=\"red\">-1.7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1481881\" data-linked=\"After Hour Gainers / Losers\" data-tweet=\"$JKS $YGE $SVXY - After Hour Gainers / Losers https://seekingalpha.com/news/1481881-after-hour-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/1481881-after-hour-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1481751\" data-ts=\"1387906555\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IDCC\" target=\"_blank\">IDCC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1481751-interdigital-rallies-following-huawei-agreement-licensing-deal-expected\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">InterDigital rallies following Huawei agreement; licensing deal expected</a></h4><ul>\n<li>InterDigital's (<a href=\"https://seekingalpha.com/symbol/IDCC\" title=\"InterDigital, Inc.\">IDCC</a> <font color=\"green\">+3.6%</font>) <a href=\"https://seekingalpha.com/currents/post/1481091\" target=\"_blank\">arbitration deal</a> with Huawei, which comes shortly after the ITC <a href=\"https://seekingalpha.com/currents/post/1476021\" target=\"_blank\">ruled against</a> InterDigital in a patent suit against Huawei, Nokia, and ZTE, is expected to eventually yield \"a global licensing agreement,\" <a href=\"http://www.bloomberg.com/news/2013-12-24/interdigital-gains-after-settling-with-huawei-on-patents.html\" target=\"_blank\">says</a> InterDigital CEO Wiliiam Merritt.</li>\n<li>The company's disputes with Nokia (in the process of selling its phone business to Microsoft) and ZTE are still outstanding. Shares remain 7% below where they traded prior to the ITC ruling, and are <font color=\"red\">down 27%</font> YTD in a year the Nasdaq is up over 30%.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1481751\" data-linked=\"InterDigital rallies following Huawei agreement; licensing deal expected\" data-tweet=\"$IDCC - InterDigital rallies following Huawei agreement; licensing deal expected https://seekingalpha.com/news/1481751-interdigital-rallies-following-huawei-agreement-licensing-deal-expected?source=tweet\" data-url=\"https://seekingalpha.com/news/1481751-interdigital-rallies-following-huawei-agreement-licensing-deal-expected\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1481711\" data-ts=\"1387904892\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWTR\" target=\"_blank\">TWTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1481711-twitter-continues-rally-wunderlich-sees-short-covering-cult-status-at-play\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Twitter continues rally; Wunderlich sees short-covering, &quot;cult status&quot; at play</a></h4><ul>\n<li>Wunderlich's Blake Harper, who <a href=\"https://seekingalpha.com/currents/post/1418022\" target=\"_blank\">launched coverage</a> on Twitter (<a href=\"https://seekingalpha.com/symbol/TWTR\" title=\"Twitter, Inc.\">TWTR</a> <font color=\"green\">+7.3%</font>) with a Sell on Nov. 18 and <a href=\"https://seekingalpha.com/currents/post/1438311\" target=\"_blank\">reiterated his view</a> on Nov. 29, suspects the microblogging service's \"<a href=\"http://www.streetinsider.com/Analyst+Comments/Twitter+%28TWTR%29+Graduates+to+Cult+Status%3B+Analyst+Reiterates+Sell/9006579.html\" target=\"_blank\">cult status</a>\" among investors is contributing to its huge gains. \"It appears valuation metrics are irrelevant and that investors are betting aggressively on Twitter being the next great media-technology platform.\"</li>\n<li>Harper also notes 22% of Twitter's float was shorted as of Nov. 29, and that the float consists of just 11% of diluted shares outstanding. \"There is $5.2 billion of public investor capital supporting the $46 billion market cap.\"</li>\n<li>Also possibly helping Twitter's cause: End-of-year \"<a href=\"http://www.investopedia.com/terms/w/windowdressing.asp\" target=\"_blank\">window dressing</a>\" by fund managers, and the enthusiasm generated by the company's recent <a href=\"https://seekingalpha.com/currents/post/1463091\" target=\"_blank\">ad product barrage</a>.</li>\n<li>Shares are now <strong><font color=\"green\">up 164%</font></strong> from their $26 IPO price.</li>\n<li>\n<a href=\"https://seekingalpha.com/currents/post/1480481\" target=\"_blank\">Yesterday:</a> Twitter soars again; valuation reaches stratospheric levels</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1481711\" data-linked=\"Twitter continues rally; Wunderlich sees short-covering, &quot;cult status&quot; at play\" data-tweet=\"$TWTR - Twitter continues rally; Wunderlich sees short-covering, &quot;cult status&quot; at play https://seekingalpha.com/news/1481711-twitter-continues-rally-wunderlich-sees-short-covering-cult-status-at-play?source=tweet\" data-url=\"https://seekingalpha.com/news/1481711-twitter-continues-rally-wunderlich-sees-short-covering-cult-status-at-play\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1481681\" data-ts=\"1387903694\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBYI\" target=\"_blank\">PBYI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1481681-bofa-talks-neratinib-potential-in-lung-and-breast-cancer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BofA talks neratinib potential in lung and breast cancer</a></h4><ul>\n<li>Details from BofA's bullish note on Puma Biotechnology (<a href=\"https://seekingalpha.com/symbol/PBYI\" title=\"Puma Biotechnology, Inc.\">PBYI</a> <font color=\"green\">+5.6%</font>) are available. (<a href=\"https://seekingalpha.com/currents/post/1481351\" target=\"_blank\">previous</a>)</li>\n<li>Analyst Rachel McMinn says <a href=\"https://seekingalpha.com/currents/search?query=neratinib\" target=\"_blank\">neratinib</a> results \"<a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/13/12/4178758/update-bank-of-america-raises-po-on-puma-biotech-on-ongo\" target=\"_blank\">establish strong proof of principle</a> anti-tumor activity ...  in Her2 driven cancers.\"</li>\n<li>McMinn is \"most confident in the lung and breast cancer opportunities, but notes  that initial anti-tumor activity was observed in two additional tumors  in the basket study.\"</li>\n<li>Recall that BofA sees \"an additional ~$100/share <a href=\"https://seekingalpha.com/currents/post/1468921\" target=\"_blank\">upside  potential</a> in a positive scenario [and] an additional $40-50/share  upside\" in the event data on Her2 mutant cancer is positive. </li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1481681\" data-linked=\"BofA talks neratinib potential in lung and breast cancer\" data-tweet=\"$PBYI - BofA talks neratinib potential in lung and breast cancer https://seekingalpha.com/news/1481681-bofa-talks-neratinib-potential-in-lung-and-breast-cancer?source=tweet\" data-url=\"https://seekingalpha.com/news/1481681-bofa-talks-neratinib-potential-in-lung-and-breast-cancer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:48 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1481671\" data-ts=\"1387903605\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BB\" target=\"_blank\">BB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1481671-blackberry-adds-to-gains-in-spite-of-bearish-commentary\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BlackBerry adds to gains in spite of bearish commentary</a></h4><ul>\n<li>BlackBerry (BBRY <font color=\"green\">+2.7%</font>) is now <font color=\"green\">up 23%</font> from where it traded going into Friday morning's FQ3 report, as shorts continue covering and investors give a thumbs-up to interim CEO John Chen's plan to <a href=\"https://seekingalpha.com/currents/post/1476941\" target=\"_blank\">shift a large chunk</a> of the company's smartphone R&amp;D work to Foxconn, and thereby aid the company's efforts to <a href=\"https://seekingalpha.com/currents/post/1477841\" target=\"_blank\">become profitable by FY16</a>.</li>\n<li>The gains come even though many on the sell-side have urged investors to take profits. <a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/13/12/4176547/update-hudson-square-research-downgrades-blackberry-foll\" target=\"_blank\">Hudson Square Research</a>, which cut shares to Sell <a href=\"https://seekingalpha.com/currents/post/1479301\" target=\"_blank\">yesterday</a>, is worried about plunging service revenue (-36% Y/Y in FQ3) and \"an uncertain path for converting enterprise customers to a material per-user recurring fee.\" <a href=\"http://www.streetinsider.com/Short+Sales/BlackBerry+%28BBRY%29+Stock+Overreacted%2C+Could+be+a+Short+Into+Year-End+as+Cash+Burn+in+Focus+-+Bernstein/9003559.html\" target=\"_blank\">Bernstein</a>, meanwhile, is worried about BlackBerry's cash burn.</li>\n<li>\n<a href=\"http://www.streetinsider.com/Analyst+Comments/BlackBerry+%28BBRY%29+Target+Bumped+Slightly+Higher+at+FBR+Capital%3B+Underperform+Maintained/9003709.html\" target=\"_blank\">FBR</a> has reiterated an Underperform, and thinks BlackBerry's phone business will likely \"need a few quarters before showing signs of recovery.\" At the same time, the firm is pleased Chen provided what it considers \"a candid and sobering assessment of [a] business that is in desperate need of a new and profitable direction.\"</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1481671\" data-linked=\"BlackBerry adds to gains in spite of bearish commentary\" data-tweet=\"$BB - BlackBerry adds to gains in spite of bearish commentary https://seekingalpha.com/news/1481671-blackberry-adds-to-gains-in-spite-of-bearish-commentary?source=tweet\" data-url=\"https://seekingalpha.com/news/1481671-blackberry-adds-to-gains-in-spite-of-bearish-commentary\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1481661\" data-ts=\"1387903297\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EROC\" target=\"_blank\">EROC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1481661-eagle-rock-extends-gains-plus-6_4-percent-after-wells-fargo-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eagle Rock extends gains, +6.4% after Wells Fargo upgrade</a></h4><ul>     <li>Wells Fargo weighs in on Eagle Rock Energy's (<a href=\"https://seekingalpha.com/symbol/EROC\" title=\"Eagle Rock Energy Partners, L.P.\">EROC</a> <font color=\"green\">+6.4%</font>) <a href=\"https://seekingalpha.com/currents/post/1479051\" target=\"_blank\">$1.3B midstream asset sale</a> to Regency Energy, <a href=\"http://www.streetinsider.com/Upgrades/Wells+Fargo+Upgrades+Eagle+Rock+Energy+%28EROC%29+to+Outperform+Following+Asset+Sale/9006219.html\" target=\"_blank\">upgrading</a> shares to Outperform from Market Perform with a $7-$8 price target, up from $6-$8.</li>     <li>Even after <a href=\"https://seekingalpha.com/currents/post/1480781\" target=\"_blank\">yesterday's 12.5% rise</a>, EROC's upside potential from the transaction is not yet fully reflected in the current valuation, since the asset sale de-risks its business, analyst Praneeth Satish writes.</li>     <li>Wells sees several favorable results from the deal, such as elimination of near-term equity needs, utilizing its under-levered balance sheet to make accretive upstream asset acquisitions, and visible 5% average annual growth over the next three years.</li>     <li>The asset sale \"transforms EROC into a pure-play upstream MLP, which implies further upside potential based on EROC\u2019s current valuation vs. the peer group.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"1481661\" data-linked=\"Eagle Rock extends gains, +6.4% after Wells Fargo upgrade\" data-tweet=\"$EROC - Eagle Rock extends gains, +6.4% after Wells Fargo upgrade https://seekingalpha.com/news/1481661-eagle-rock-extends-gains-plus-6_4-percent-after-wells-fargo-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/1481661-eagle-rock-extends-gains-plus-6_4-percent-after-wells-fargo-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1481621\" data-ts=\"1387901738\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1481621-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li>\n<b>Top 10 Gainers:</b> <a href=\"https://seekingalpha.com/symbol/BASI\" title=\"Bioanalytical Systems, Inc.\">BASI</a> <font color=\"green\">+26%</font>. <a href=\"https://seekingalpha.com/symbol/ORMP\" title=\"Oramed Pharmaceuticals Inc.\">ORMP</a> <font color=\"green\">+26%</font>. <a href=\"https://seekingalpha.com/symbol/IDIX\" title=\"Idenix Pharmaceuticals, Inc.\">IDIX</a> <font color=\"green\">+21%</font>. <a href=\"https://seekingalpha.com/symbol/NFEC\" title=\"NF Energy Saving Corp.\">NFEC</a> <font color=\"green\">+17%</font>. <a href=\"https://seekingalpha.com/symbol/VBFC\" title=\"Village Bank and Trust Financial Corp.\">VBFC</a> <font color=\"green\">+15%</font>. <a href=\"https://seekingalpha.com/symbol/CYTR\" title=\"CytRx Corporation\">CYTR</a> <font color=\"green\">+13%</font>. <a href=\"https://seekingalpha.com/symbol/NED\" title=\"Noah Education Holdings Ltd.\">NED</a> <font color=\"green\">+13%</font>. <a href=\"https://seekingalpha.com/symbol/ATOS\" title=\"Atossa Genetics, Inc.\">ATOS</a> <font color=\"green\">+13%</font>. <a href=\"https://seekingalpha.com/symbol/SUPN\" title=\"Supernus Pharmaceuticals, Inc.\">SUPN</a> <font color=\"green\">+12%</font>. <a href=\"https://seekingalpha.com/symbol/WLB\" title=\"Westmoreland Coal Co\">WLB</a> <font color=\"green\">+11%</font>.</li>\n<li>\n<b>Top 10 Losers:</b> <a href=\"https://seekingalpha.com/symbol/ENZN\" title=\"Enzon Pharmaceuticals, Inc.\">OTC:ENZN</a> <font color=\"red\">-28%</font>. <a href=\"https://seekingalpha.com/symbol/DGSE\" title=\"DGSE Companies, Inc\">DGSE</a> <font color=\"red\">-10%</font>. <a href=\"https://seekingalpha.com/symbol/CAMP\" title=\"CalAmp Corp.\">CAMP</a> <font color=\"red\">-9%</font>. <a href=\"https://seekingalpha.com/symbol/STRI\" title=\"STR Holdings, Inc.\">STRI</a> <font color=\"red\">-5%</font>. <a href=\"https://seekingalpha.com/symbol/OTIV\" title=\"On Track Innovations Ltd\">OTIV</a> <font color=\"red\">-6%</font>. <a href=\"https://seekingalpha.com/symbol/DL\" title=\"China Distance Education Holdings Limited\">DL</a> <font color=\"red\">-6%</font>. <a href=\"https://seekingalpha.com/symbol/SPRO\" title=\"Spero Therapeutics, Inc.\">SPRO</a> <font color=\"red\">-6%</font>. TRMR <font color=\"red\">-6%</font>. <a href=\"https://seekingalpha.com/symbol/PULS-OLD\" title=\"Pulse Electronics Corporation\">PULS-OLD</a> <font color=\"red\">-7%</font>. <a href=\"https://seekingalpha.com/symbol/CAMT\" title=\"Camtek Ltd.\">CAMT</a> <font color=\"red\">-5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1481621\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$BASI $ORMP $IDIX - Midday Gainers / Losers https://seekingalpha.com/news/1481621-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/1481621-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1481591\" data-ts=\"1387901120\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANH\" target=\"_blank\">ANH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1481591-anworth-boosted-by-buyback-plan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Anworth boosted by buyback plan</a></h4><ul>\n<li>Anworth (<a href=\"https://seekingalpha.com/symbol/ANH\" title=\"Anworth Mortgage Asset Corporation\">ANH</a> <font color=\"green\">+1.6%</font>) gains after boosting its stock repurchase program by 5M shares. Thus far this quarter, the company has bought back 2.8M shares vs. a float of 140M.</li>\n<li>Earlier this month, Anworth <a href=\"https://seekingalpha.com/currents/post/1464901\" target=\"_blank\">slashed its quarterly dividend</a> by 33% to $0.08 per share. The payout was $0.12 in Q3 and $0.15 a quarter before that. The annualized yield of 7.6% is light for the mREITs, but the discount to Sept. 30 book of 30% is large even by the standards of the beaten-up sector.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1481591\" data-linked=\"Anworth boosted by buyback plan\" data-tweet=\"$ANH - Anworth boosted by buyback plan https://seekingalpha.com/news/1481591-anworth-boosted-by-buyback-plan?source=tweet\" data-url=\"https://seekingalpha.com/news/1481591-anworth-boosted-by-buyback-plan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:05 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1481531\" data-ts=\"1387898877\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COLUF\" target=\"_blank\">COLUF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1481531-colossus-minerals-plus-23_5-percent-despite-low-project-resource-estimate\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Colossus Minerals +23.5% despite low project resource estimate</a></h4><ul>     <li>Colossus Minerals (<a href=\"https://seekingalpha.com/symbol/COLUF\" title=\"Colossus Minerals Inc.\">OTC:COLUF</a> <font color=\"green\">+23.5%</font>), already on the brink of financial collapse, released a mineral resource estimate yesterday for its Serra Pelada project in Brazil that identified a <a href=\"http://business.financialpost.com/2013/12/23/colossus-shocks-market-with-cancelled-financing-low-resource-estimate/\" target=\"_blank\">miniscule 274K oz. of gold</a>.</li>     <li>Investors had figured the site contained millions of ounces and are hoping the 274K calculation is too low, since the geology of the deposit may not mesh well with resource reporting rules in Canada; many of the high-grade portions of the deposit did not get into the estimate.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1481531\" data-linked=\"Colossus Minerals +23.5% despite low project resource estimate\" data-tweet=\"$COLUF - Colossus Minerals +23.5% despite low project resource estimate https://seekingalpha.com/news/1481531-colossus-minerals-plus-23_5-percent-despite-low-project-resource-estimate?source=tweet\" data-url=\"https://seekingalpha.com/news/1481531-colossus-minerals-plus-23_5-percent-despite-low-project-resource-estimate\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:27 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1481491\" data-ts=\"1387898057\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KNDI\" target=\"_blank\">KNDI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1481491-kandi-technologies-rallies-jv-acquires-full-control-of-ev-company\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kandi Technologies rallies; JV acquires full control of EV company</a></h4><ul>\n<li>A JV company that's 50%-owned by Kandi Technologies (<a href=\"https://seekingalpha.com/symbol/KNDI\" title=\"Kandi Technologies Group, Inc.\">KNDI</a> <font color=\"green\">+8.2%</font>) is paying RMB640.6M ($104.1M) to assume full ownership of Kandi Electric Vehicles (i.e. Kandi Shanghai) from Shanghai Maple, a subsidiary of Chinese automaker Geely. $65M will be paid within 90 days of the deal's signing, and the remainder will be paid within 360 days of signing. (PR)</li>\n<li>Kandi asserts the deal \"better consolidates the resources and expertise of Kandi and Geely\" in EV R&amp;D, manufacturing, sales, and marketing.</li>\n<li>Kandi <a href=\"https://seekingalpha.com/currents/post/907851\" target=\"_blank\">formed a JV</a> with Shanghai Maple in March; each company contributed $80M.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1481491\" data-linked=\"Kandi Technologies rallies; JV acquires full control of EV company\" data-tweet=\"$KNDI - Kandi Technologies rallies; JV acquires full control of EV company https://seekingalpha.com/news/1481491-kandi-technologies-rallies-jv-acquires-full-control-of-ev-company?source=tweet\" data-url=\"https://seekingalpha.com/news/1481491-kandi-technologies-rallies-jv-acquires-full-control-of-ev-company\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:14 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1481391\" data-ts=\"1387896182\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GLUU\" target=\"_blank\">GLUU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1481391-glu-mobile-falls-on-b-riley-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Glu Mobile falls on B. Riley downgrade</a></h4><ul><li>Two months after Glu Mobile (<a href='https://seekingalpha.com/symbol/GLUU' title='Glu Mobile Inc.'>GLUU</a> <font color='red'>-5.4%</font>) was <a href=\"https://seekingalpha.com/currents/post/1326192\" target=\"_blank\">upgraded</a> to Buy by B. Riley, shares have been downgraded back to Neutral on account of valuation.</li><li>Aided by <em>Deer Hunter 2014</em>'s <a href=\"https://seekingalpha.com/currents/post/1319272\" target=\"_blank\">strong performance</a>, Glu had <font color='green'>risen 36%</font> from the time of B. Riley's upgrade to yesterday's close. Consensus estimates have also <a href=\"http://finance.yahoo.com/q/ae?s=GLUU+Analyst+Estimates\" target=\"_blank\">moved higher</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"1481391\" data-linked=\"Glu Mobile falls on B. Riley downgrade\" data-tweet=\"$GLUU - Glu Mobile falls on B. Riley downgrade https://seekingalpha.com/news/1481391-glu-mobile-falls-on-b-riley-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/1481391-glu-mobile-falls-on-b-riley-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1481351\" data-ts=\"1387895356\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBYI\" target=\"_blank\">PBYI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1481351-puma-biotechnology-continues-to-climb-as-analysts-giddy-over-neratinib\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Puma Biotechnology continues to climb as analysts giddy over neratinib</a></h4><ul>\n<li>Puma Biotechnology (NYSE:<a href=\"https://seekingalpha.com/symbol/PBYI\" title=\"Puma Biotechnology, Inc.\">PBYI</a>) jumps <font color=\"green\">5%</font> before the bell on the heels of Monday night's <a href=\"https://seekingalpha.com/currents/search?query=neratinib\" target=\"_blank\">neratinib</a> call (see <a href=\"https://event.webcasts.com/starthere.jsp?ei=1027207\" target=\"_blank\">here</a>).</li>\n<li>Meanwhile, the sell-side is busy one-upping each other with price target hikes.</li>\n<li>BofA is reportedly out <a href=\"https://twitter.com/bradloncar/status/415364048083877888\" target=\"_blank\">lifting</a> its price objective to $141. That looks like the third raise this month (see <a href=\"https://seekingalpha.com/currents/post/1468921\" target=\"_blank\">here</a> and <a href=\"https://seekingalpha.com/currents/post/1447711\" target=\"_blank\">here</a>).</li>\n<li>Market chatter <a href=\"https://twitter.com/zbiotech/status/415473102349275136\" target=\"_blank\">suggests</a> Leerink's target is now $144.</li>\n<li>Investors can probably expect more bullish calls to come.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1481351\" data-linked=\"Puma Biotechnology continues to climb as analysts giddy over neratinib\" data-tweet=\"$PBYI - Puma Biotechnology continues to climb as analysts giddy over neratinib https://seekingalpha.com/news/1481351-puma-biotechnology-continues-to-climb-as-analysts-giddy-over-neratinib?source=tweet\" data-url=\"https://seekingalpha.com/news/1481351-puma-biotechnology-continues-to-climb-as-analysts-giddy-over-neratinib\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1481341\" data-ts=\"1387895299\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NED\" target=\"_blank\">NED</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1481341-noah-education-plus-15_5-percent-after-receiving-going-private-proposal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Noah Education +15.5% after receiving going-private proposal</a></h4><ul>\n<li>Noah Education (NYSE:<a href=\"https://seekingalpha.com/symbol/NED\" title=\"Noah Education Holdings Ltd.\">NED</a>) <font color=\"green\">+15.5%</font> premarket on news that some of its shareholders have proposed taking the company private for ~$105M, and NED has formed a special committee to evaluate the proposal.</li>\n<li>Some shareholders of the China-based education company, including an affiliate of Morgan Stanley's P-E arm in Asia, will offer the remaining holders $2.80/share, a 24% premium to Monday\u2019s close of $2.25.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1481341\" data-linked=\"Noah Education +15.5% after receiving going-private proposal\" data-tweet=\"$NED - Noah Education +15.5% after receiving going-private proposal https://seekingalpha.com/news/1481341-noah-education-plus-15_5-percent-after-receiving-going-private-proposal?source=tweet\" data-url=\"https://seekingalpha.com/news/1481341-noah-education-plus-15_5-percent-after-receiving-going-private-proposal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1481271\" data-ts=\"1387894225\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1481271-premarket-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers / Losers</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ATOS' title='Atossa Genetics, Inc.'>ATOS</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/SUPN' title='Supernus Pharmaceuticals, Inc.'>SUPN</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/BASI' title='Bioanalytical Systems, Inc.'>BASI</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/IDCC' title='InterDigital, Inc.'>IDCC</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/CLWT' title='Euro Tech Holdings Company Limited'>CLWT</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/KNDI' title='Kandi Technologies Group, Inc.'>KNDI</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CAMP' title='CalAmp Corp.'>CAMP</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"1481271\" data-linked=\"Premarket Gainers / Losers\" data-tweet=\"$ATOS $SUPN $BASI - Premarket Gainers / Losers https://seekingalpha.com/news/1481271-premarket-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/1481271-premarket-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1481231\" data-ts=\"1387893528\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATOS\" target=\"_blank\">ATOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1481231-atossa-genetics-rallies-on-hopes-for-forecyte\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Atossa Genetics rallies on hopes for ForeCYTE</a></h4><ul>\n<li>Shares of Atossa Genetics (NASDAQ:<a href=\"https://seekingalpha.com/symbol/ATOS\" title=\"Atossa Genetics, Inc.\">ATOS</a>) rally<font color=\"green\"> 20%</font> premarket as the company submits a premarket 510(k) notification to the FDA for the ForeCYTE Breast Aspirator.</li>\n<li>The company notes that the regulator usually makes a decision within 90 days.</li>\n<li>The product will be re-launched upon clearance. (PR)</li>\n<li>For reference on this story, see <a href=\"https://seekingalpha.com/currents/post/1315752\" target=\"_blank\">here</a> and <a href=\"https://seekingalpha.com/currents/post/1464061\" target=\"_blank\">here</a>.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1481231\" data-linked=\"Atossa Genetics rallies on hopes for ForeCYTE\" data-tweet=\"$ATOS - Atossa Genetics rallies on hopes for ForeCYTE https://seekingalpha.com/news/1481231-atossa-genetics-rallies-on-hopes-for-forecyte?source=tweet\" data-url=\"https://seekingalpha.com/news/1481231-atossa-genetics-rallies-on-hopes-for-forecyte\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1481071\" data-ts=\"1387890065\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMUC\" target=\"_blank\">IMUC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1481071-immunocellular-talks-cancer-vaccine-program-shares-rally\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ImmunoCellular talks cancer vaccine program, shares rally</a></h4><ul>\n<li>Shares of ImmunoCellular (<a href=\"https://seekingalpha.com/symbol/IMUC\" title=\"ImmunoCellular Therapeutics, Ltd.\">OTCPK:IMUC</a>) are trading sharply higher in premarket action.</li>\n<li>Notably, the company provides a bit of commentary on ICT-107 which, investors will recall, was behind a dramatic decline in IMUC's shares earlier this month when the OS K-M curves <a href=\"https://seekingalpha.com/currents/post/1460251\" target=\"_blank\">failed to hit statistical significance</a> in a Phase 2 study.<br>\n</li>\n<li>IMUC says it \"urges patients and other stakeholders to look beyond the       unsubstantiated commentary on the recent trial results to what [the company] and       clinical experts believe are important findings from this clinical       program to date.\"</li>\n<li>Further, IMUC says \"nationally renowned neuro-oncologists ... share [the company's] view that as the survival data mature in 2014, there is       the potential to see clarification of the survival benefit of the       ICT-107 treated group.\" (PR)</li>\n<li>IMUC <font color=\"green\">+20%</font> premarket</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1481071\" data-linked=\"ImmunoCellular talks cancer vaccine program, shares rally\" data-tweet=\"$IMUC - ImmunoCellular talks cancer vaccine program, shares rally https://seekingalpha.com/news/1481071-immunocellular-talks-cancer-vaccine-program-shares-rally?source=tweet\" data-url=\"https://seekingalpha.com/news/1481071-immunocellular-talks-cancer-vaccine-program-shares-rally\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1480891\" data-ts=\"1387880566\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1480891-world-stocks-head-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">World stocks head higher</a></h4><ul>   <li>Global equities are <a href=\"http://uk.reuters.com/article/2013/12/24/markets-global-idUKL6N0JV32P20131224\" target=\"_blank\">mostly higher</a> following another strong day on Wall Street yesterday and ahead of the early close in Europe and the Americas for Christmas.</li>    <li><a href=\"http://www.marketwatch.com/story/asia-stocks-rise-as-tokyo-hits-six-year-high-2013-12-23\" target=\"_blank\">Japan's Nikkei</a> ended <font color='green'>+0.1%</font> at 15,889.33, its highest level since December 2007. The country's stocks have jumped 54% this year, fueled by the Bank of Japan's massive asset-buying.</li><li>China's Shanghai Composite finished <font color='green'>+0.15%</font> as the latest squeeze on credit <a href=\"https://seekingalpha.com/currents/post/1480851\" target=\"_blank\">started to ease</a>.</li>    <li>Elsewhere in Asia, the Hang Seng <font color='green'>climbed 1.1%</font>, although India's Sensex <font color='red'>fell 0.3%</font>.</li>    <li>London <font color='green'>+0.4%</font>, Paris <font color='green'>+0.2%</font>, Madrid <font color='green'>+0.6%</font>.</li>     <li>U.S. stock futures: Dow <font color='green'>+0.1%</font>. S&amp;P <font color='green'>+0.1%</font>. Nasdaq flat.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1480891\" data-linked=\"World stocks head higher\" data-tweet=\"World stocks head higher https://seekingalpha.com/news/1480891-world-stocks-head-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/1480891-world-stocks-head-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:22 AM </div></div></li>","count":17,"message":null,"success":true,"today":{"start":1576818000,"end":1576904399,"str":"Friday, December 20, 2019"},"yesterday":{"start":1576731600,"end":1576817999}}